CompletedNot Applicable

TSI and Its Relationship With Graves' Disease Relapse

Vietnam352 participantsStarted 2022-01-02

Plain-language summary

The goal of this observational study is to determine the role of TSI, as well as clinical signs and thyroid function tests in predicting Graves' disease (GD) relapse after withdrawing anti thyroid drug (ATD). The main questions it aims to answer are: 1. To investigate the serum TSI concentration in patients with GD undergoing maintenance-dose ATD. 2. To determine an optimal cut-off of TSI level for predicting GD relapse. 3. To determine the role of TSI in predicting Graves' disease relapse after withdrawing ATD.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with hyperthyroidism due to Graves' disease according to the criteria of the Japan Thyroid Association. * TSI: measured during the course of treatment when planning to stop medication (normal FT4 at maintenance-dose of ATD) Methimazole (MMI): at doses of ≤10 mg. Propylthiouracil (PTU): at doses of ≤200 mg. Exclusion Criteria: * Hyperthyroidism due to other causes * Patients who were intolerant to ATD or had serious side effects with ATD. * TSIs were measured in pregnancy. * Patients treated with surgery or radioactive iodine.

What they're measuring

Number of Participants with GD relapse

Timeframe: at least 1 year after ATD withdrawal

Trial details

NCT IDNCT05713097

SponsorUniversity of Medicine and Pharmacy at Ho Chi Minh City

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-08-31

View on ClinicalTrials.gov More Graves Disease trials